PDF(Pubmed)
Abstract：
N-3-[18F]fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane ([18F]FP-CIT) is a radiopharmaceutical for dopamine transporter (DAT) imaging using positron emission tomography (PET) to detect dopaminergic neuronal degeneration in patients with parkinsonian syndrome. [18F]FP-CIT was granted approval by the Ministry of Food and Drug Safety in 2008 as the inaugural radiopharmaceutical for PET imaging, and it has found extensive utilization across numerous institutions in Korea. This review article presents an imaging procedure for [18F]FP-CIT PET to aid nuclear medicine physicians in clinical practice and systematically reviews the clinical studies associated with [18F]FP-CIT PET.
摘要：
N-3-[18F]氟丙基-2β-甲氧甲氧基-3β-4-碘苯基去甲托烷（[18F]FP-CIT）是一种使用正电子发射断层扫描（PET）检测多巴胺能神经元变性的放射性药物。帕金森病综合征患者。[18F]FP-CIT于2008年获得食品和药物安全部的批准，成为首个用于PET成像的放射性药物，它已经在韩国的许多机构中得到了广泛的利用。本文介绍了[18F]FP-CITPET的成像程序，以帮助核医学医师进行临床实践，并系统地回顾了与[18F]FP-CITPET相关的临床研究。
